Oral ATRA treatment for adult HLH
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests an oral drug called all-trans retinoic acid (ATRA) for adults with HLH, a serious immune system problem. It may help calm the overactive immune response and reduce organ damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have active HLH (a condition where your immune system overreacts and damages organs), or you show signs like fever, low blood counts, or an enlarged spleen.
- You have not had strong HLH treatments before (like etoposide, ruxolitinib, or emapalumab).
- You can take medicine by mouth or through a feeding tube.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, emapalumab and ruxolitinib, for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages organs. The goal is to control the disease with fewer side effects than standard treatments.
This trial tests a new combination of two medicines, pembrolizumab and ATRA (a form of vitamin A), for people with certain lymphomas that have come back or stopped responding to earlier treatments. The goal is to see if the combination can help the immune system fight the cancer more effectively.
This trial tests a medicine called ATRA (a form of vitamin A) to see if it can help adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing bleeding and bruising. It is for people who have already tried standard treatments without lasting success.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This study looks at how well first-time treatment with ATO plus ATRA works in adults with acute promyelocytic leukemia (APL). It mainly checks treatment results in real life, including whether patients reach “molecular remission” (very deep disease control).
This trial tests whether giving a combination of two oral medicines—realgar-indigo naturalis formula (RIF) and all-trans retinoic acid (ATRA)—early in treatment can help people with acute promyelocytic leukemia (APL), a specific type of blood cancer. The goal is to see if this approach works better than current standard care.
Hear when a new Hemophagocytic Lymphohistiocytosis (HLH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.